Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:32:37.116Z.
Calculation as of: 2026-10-06T21:32:37.116Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7de7752a9f7c92cf302168b3adc2b8952dbd3ee015c15fa7e623ade4200d4f53
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Jade Biosciences, Inc.
Market Cap
$816.13M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$817.67M
Operating Cash Flow Yield
N/A
TTM Avg
26.54%
3Y Avg
24.23%
5Y Avg
24.23%
Market Cap
$804.16M
Operating Cash Flow Yield
11.01%
TTM Avg
10.22%
3Y Avg
10.24%
5Y Avg
8.00%
Market Cap
$828.48M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833.81M
Operating Cash Flow Yield
N/A
TTM Avg
10.89%
3Y Avg
10.89%
5Y Avg
10.89%
Market Cap
$838.16M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$838.62M
Operating Cash Flow Yield
N/A
TTM Avg
1.45%
3Y Avg
1.45%
5Y Avg
1.45%
Market Cap
$789.34M
Operating Cash Flow Yield
N/A
TTM Avg
0.41%
3Y Avg
2.06%
5Y Avg
3.27%
Market Cap
$785.03M
Operating Cash Flow Yield
74.30%
TTM Avg
47.32%
3Y Avg
42.03%
5Y Avg
31.48%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $816.13M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | N/A | 26.54% | 24.23% | 24.23% |
| InMode Ltd. (INMD)vs › | $804.16M | 11.01% | 10.22% | 10.24% | 8.00% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $828.48M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | N/A | 10.89% | 10.89% | 10.89% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | 1.45% | 1.45% | 1.45% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $789.34M | N/A | 0.41% | 2.06% | 3.27% |
| AdaptHealth Corp. (AHCO)vs › | $785.03M | 74.30% | 47.32% | 42.03% | 31.48% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
